4th November, 2008
Evolva receives funding from the Global Cardiovascular Innovation Center
Evolva today announced that it has received a $288,000 award from the Cleveland Clinic led Global Cardiovascular Innovation Center (GCIC). The funding is to advance the development of Evolva’s EV-077 compound series for cardiovascular disease and to explore the formation of a dedicated cardiovascular clinical unit to be based in Cleveland, Ohio. [Read more]
• • •
30th September, 2008
Evolva appoints new advisors
Evolva SA, an international biotech company which develops drugs
with genetic chemistry, has expanded its Scientific Advisor team by appointing Jessica Mann and Michael S.
Marriott. [Read more]
• • •
12th August, 2008
Evolva India Announces 3 Collaborations
Evolva’s Genetic Chemistry Laboratory, has received recognition from the
Government of India’s Department of Science and Industrial Research (DSIR). [Read more]
• • •
19th May, 2008
Evolva Subsidiary Signs $22.8 Million Antibacterial Contract with US Army Research Office, Builds Out US Operations
Genetic Chemistry Inc. (Palo Alto, USA), a subsidiary of Evolva SA (Basel, Switzerland) announced today that it has signed a contract with the US Army Research Office (ARO), working in conjunction with the Defense Threat Reduction Agency (DTRA), to discover novel therapeutics against the gram negative bacterial pathogen Burkholderia pseudomallei (a CDC category B bioterrorism agent that causes the disease melioidosis). Over the contract period funding could amount to $22.8 million. [Read more]
• • •
1st September, 2007
New CFO at Evolva
Jakob D. Hansen has joined Evolva SA, the Swiss-based biotech company, as Chief Financial Officer. [Read more]
• • •
2nd July, 2007
Evolva and Summit sign collaboration to develop anti-infectives
Evolva SA and Summit have entered into a collaboration for co-development of immuno-modulators for the treatment and prevention of certain infectious diseases. [Read more]
• • •
1st July, 2007
Sandy Dobbie becomes new chairman at Evolva
Sandy Dobbie has been elected new chairman at Evolva SA. The former chairman, Jean-Philippe Tripet, Managing Partner of Aravis Venture, will remain a member of the board of Evolva. [Read more]
• • •
1st January, 2007
Evolva led consortium receives a € 3.4 million Cancer research grant from EC
Evolva led consortium received € 3.4 million for funding a three year cancer research program on protein-protein interaction. [Read more]
• • •
20th December, 2006
Evolva Announces Collaboration with Functional Genetics on $ 28 Million Award
The program will, over a four year period, discover and develop compounds through to the filing of Investigational New Drug applications [Read more]
• • •
1st December, 2006
Evolva raises CHF 12 million in new equity financing
Evolva SA has received binding commitments for CHF 12 million (USD 10.3 million) in a second round of its Series A financing. [Read more]
• • •
8th November, 2006
Evolva Receives Award from the United States Defense Threat Reduction Agency
Evolva today announced that it has received a $26.7 million award from the United States Defense Threat Reduction Agency (DTRA)... [Read more]
• • •
2nd September, 2005
Evolva Acquires Pharmaceutical Business of Poalis
Evolva SA and Poalis A/S announced today that Evolva has acquired the pharmaceutical business and associated assets of Poalis... [Read more]
• • •
21st March, 2005
Evolva establishes Indian Operations
Evolva has raised a further CHF 3.0 million in a final closing of its A-round. New investor APIDC-VC led the financing with smaller participations from existing investors... [Read more]
• • •
16th August, 2004
Evolva raises € 12 million A-round from International Investors
Evolva Biotech today announced that it has raised c. € 12 million (CHF 18.5 million, Dkr 90 million, US $ 14.9 million) of equity financing in a first-closing of its A-round... [Read more]
• • •
